SAN DIEGO – The dawn of regulator-approved chimeric antigen receptor (CAR) T-cell therapies such as Kymriah (tisagenlecleucel, Novartis AG) have provided doctors with important new options for treating people with several types of aggressive blood cancers. But how long the new therapies can help and whether their costs can be made sustainable remain open questions. New research presented at the American Society of Hematology (ASH) Annual Meeting and Exposition is shedding light on the duration question with what City of Hope's Joe Alvarnas called "practice-changing" results.